ID | 1293 |
Name of the vaccine | Tritanrix-HepB/ Hiberix |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 6 to 8 weeks |
Description of the vaccine | Low or high dose formulations of DTPw-HBV/Hib vaccine. |
Name of the manufacturer | GlaxoSmithKline |
Name of the manufacturing country | India |
Year of manufacture | 2008 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses at 6, 10 and 14 weeks of age. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For tetanus , haemophilus influenzae type b, diphtheria and hepatitis B. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (3 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00473668 |
Reference | NA |
Other name | NA |
Additional Links | NA
|